Brief: Almirall's Ilumetri Improves Psorasis Patients' Wellbeing For Up To 1 Year
28/06/2024 11:20
June 28 (Reuters) - Almirall SA ALM.MC :
* ILUMETRI RESTORES AND MAINTAINS WELLBEING OF PATIENTS WITH
MODERATE-TO-SEVERE PLAQUE PSORIASIS TO LEVELS OF GENERAL
POPULATION FOR UP TO 1 YEAR
Further company coverage: ALM.MC
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Almirall
See all newsBrief: Almirall Says Phase 3B Adlong Clinical Study Show Treatment Outcomes With Up To Five Years Of Lebrikizumab
Brief: Almirall And CrystalO To Discover, Develop Novel Small Molecules In Medical Dermatology
Almirall shares rise as lower costs beat EBITDA estimates
Brief: Almirall, Certest Biotec Sign Deal to Develop Rare Dermatology Treatments
Spanish stocks - Factors to watch on July 24